• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
CommentaryHealth

The DOGE-fueled firing of AI experts at the FDA endangers lives and worsens the hospital crisis

By
Siva Somayajula
Siva Somayajula
Down Arrow Button Icon
By
Siva Somayajula
Siva Somayajula
Down Arrow Button Icon
February 27, 2025, 5:55 PM ET

Siva Somayajula is chief technology officer at AliveCor.

Tesla CEO Elon Musk, the head of Trump's Department of Government Efficiency (DOGE).
Tesla CEO Elon Musk, the head of Trump's Department of Government Efficiency (DOGE).SAUL LOEB/AFP via Getty Images

As the Trump administration takes sweeping actions to try to improve government efficiency, unexpected side effects are arising. One of those directly impacts my field, health and medical technologies. Those of us in this industry find ourselves with a dramatically slower process for getting government approval to bring life-saving tools to the market.

This was surely unintended, and reports suggest that the government may now be scrambling to undo some of the damage. It must be rectified quickly.

In dramatically reducing the federal workforce, the Department of Government Efficiency (DOGE) cast a wide net, laying off large numbers of employees. Many of those let go were probationary employees because they were relatively new. (Federal employees generally have probationary status for the first year.)

AI brain drain

A disproportionate number of those workers were in roles that involve AI. This makes sense, since these technologies have been developing quickly. The Biden administration, in what it called an “AI talent surge,” ushered in a wave of AI experts to various roles across the executive branch last year.

Now, there’s been a sudden, rapid AI brain drain in the federal sector. This can affect every department. I see it acutely in health care, where recent AI developments have been a game changer. My company has been working tirelessly to build AI-powered devices that allow people to monitor their heart health from wherever they are. It’s a key to fighting back against the nation’s biggest killer. An estimated 80% of cardiovascular disease is preventable.

Such tools can only become available to patients with approval from the Food and Drug Administration, but the FDA has fired many of its AI experts who conduct the approvals process. Now it could take months or years longer.

I have no doubt that this loss of AI personnel was unintended. In fact, the new administration said they want the United States to lead in artificial intelligence.

Fortunately, the government has been trying to rescind some of the firings. But amid the confusion, it’s unclear how many of the workers will return. And in order to entice people who could work in the private sector for more money, the government must make it clear to AI talent that they will have job security, something many federal employees no longer have.

FDA clearance for health technology isn’t just a hurdle; it’s a necessity. Only rigorous testing, overseen and understood by those tasked with representing the public, can ensure that devices are safe to use. At AliveCor, where I work, we have been through this process many times. Last year, we got FDA approval for a portable 12-lead AI-powered ECG device, a hand-held version of the kind of machinery that provides ECGs (electrocardiograms) in hospitals. Once that approval went through, people knew they could trust the efficacy of this device.

Medtech innovation

Not only is FDA approval important, it’s also a crucial incentive for innovation. If potential creators of medical devices face a massive backlog for approval, they’ll be less likely to enter the field and create the next new tools.

Rural areas will be especially hard hit by a lack of tools like ours for remote patient monitoring (RPM). Many have no nearby hospitals or medical centers and have become “health-care deserts.” More than 80% of rural counties are “medically underserved,” according to the National Association of Counties. Tools that can monitor patients at home are transformational.

Remote devices are also necessary to relieve the backlogs at hospitals. Overcrowded emergency rooms have reached crisis levels, and hospitals could face a shortage of beds in the coming years. At-home devices can monitor symptoms, spot problems, and connect patients remotely with health-care providers to offer advice and even schedule in-person appointments. This must be the future of medical care.

There are economic incentives as well. The medical devices industry is skyrocketing around the world. It’s projected to grow from $542 billion in 2024 to $887 billion by 2032, according to Fortune Business Insights. If the U.S. process is slowed, other countries will surge ahead and grab much more of the market share.

Health is also the most essential element of having a productive workforce. The faster the government restores AI expertise to the FDA, the sooner the country will be on track to building the most technologically advanced future in which people can be healthier—and more efficient.

The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.

Read more:

  • The DOGE turmoil shows why federal agencies need better branding and marketing
  • How the Trump admin transformed the U.S. into the financial Wild West in a matter of weeks
  • A veteran of the only successful government reduction effort in 30 years has a warning for Elon Musk: ‘All hell is going to break loose’
  • The federal funding freeze is inciting fear and chaos for millions with cancer. There’s a better way
Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Author
By Siva Somayajula
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

wolfgang
CommentaryLeadership
Europe doesn’t lack tech talent. Its leaders lack execution
By Wolfgang OelsMarch 3, 2026
17 hours ago
zuck
Commentarycyber
Boards aren’t ready for the AI age: What happens when your CEO gets deepfaked?
By James RichardsonMarch 3, 2026
19 hours ago
Europedigital transformation
Why Europe can lead in trusted, industrialized AI
By Dave McCannMarch 2, 2026
2 days ago
heitmann
CommentaryEntrepreneurship
Here’s how to build something that lasts, from the founder of a $300 million bootstrapped company that’s been growing for 28 years straight
By Tim HeitmannMarch 1, 2026
3 days ago
world's fair
CommentaryRobots
Something big is happening in AI, but panic is the wrong reaction
By Peter CappelliFebruary 28, 2026
4 days ago
putin
CommentaryRussia
Exclusive analysis: we looked at the 400 western firms still in Russia. Their paltry size strips Putin’s bluff bare naked
By Jeffrey Sonnenfeld, Stephen Henriques, Jake Waldinger and Giuseppe ScottoFebruary 27, 2026
5 days ago

Most Popular

placeholder alt text
Economy
Interest on the $38.8 trillion national debt has tripled since 2020, and it already costs taxpayers more than defense and Medicaid
By Nick LichtenbergMarch 2, 2026
1 day ago
placeholder alt text
Middle East
Iran’s Islamic Revolutionary Guard controls a sprawling business empire that dominates the economy
By Jason MaMarch 2, 2026
1 day ago
placeholder alt text
Middle East
U.S. military gives Iran a taste of its own medicine with cheap copycat Shahed drones, while concern shifts to munitions supply in extended conflict
By Jason MaMarch 1, 2026
2 days ago
placeholder alt text
Personal Finance
Current price of gold as of March 2, 2026
By Danny BakstMarch 2, 2026
2 days ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, March 3, 2026
By Joseph HostetlerMarch 3, 2026
14 hours ago
placeholder alt text
AI
American schools weren’t broken until Silicon Valley used a lie to convince them they were—now reading and math scores are plummeting
By Sasha RogelbergMarch 1, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.